| Autor: |
Luk BT; Department of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States., Jiang Y; Department of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States., Copp JA; Department of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States., Hu CJ; Institute of Biomedical Sciences , Academia Sinica , Taipei 11529 , Taiwan., Krishnan N; Department of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States., Gao W; Department of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States., Li S; Department of Pediatric Research , MD Anderson Cancer Center , Houston , Texas 77030 , United States., Fang RH; Department of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States., Zhang L; Department of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States. |
| Abstrakt: |
Within the body, cellular recognition is mediated in large part by receptor-ligand interactions that result from the surface marker expression of the participant cells. In the case of immune cells, these interactions can be highly specific, enabling them to carry out their protective functions in fighting off infection and malignancy. In this work, we demonstrate the biomimetic targeting of antigen-specific immune cell populations by using nanoparticles functionalized with natural membrane derived from cells expressing the cognate antigen. Using red blood cell (RBC)-specific B cells as a model target, it is shown that RBC membrane-coated nanoparticles exhibit enhanced affinity compared with control nanoparticles. The concept is further demonstrated using murine models of alloimmunity and autoimmunity, where B cells elicited against RBCs can be positively labeled using the biomimetic nanoparticles. This strategy for antigen-specific immune cell targeting may have utility for the detection and treatment of various autoimmune conditions, and it may additionally have implications for the prevention of immune cell malignancies. |
